Keywords: Merck & Co, Zymeworks, Antibody therapeutics, Parkinson's disease, Addex Pharma
Merck & Co in $187 million deal with Zymeworks to develop bi-specific antibody therapeutics; returns rights for PD drug to Addex
Article | 06 September 2011
Privately-held Canadian biotech firm Zymeworks and entered a research collaboration with US drug giant Merck & Co (NYSE: MRK) around ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Is the diabetes market facing a blockbuster-free future?
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
